ARDM Aradigm

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Aradigm Corporation – ARDM

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Aradigm Corporation (NASDAQ:ARDM) resulting from allegations that Aradigm may have issued materially misleading business information to the investing public.

On January 9, 2018, the U.S. Food and Drug Administration (“FDA”) released its briefing document for the January 11, 2018 meeting of the Antimicrobial Drugs Advisory Committee to discuss Aradigm’s New Drug Application for Linhaliq™ for the proposed indication of treatment of non-cystic fibrosis bronchiectasis (“NCFB”). The FDA briefing document stated that “[t]he Agency recommended that two adequate and well-controlled clinical trials be conducted to support the NCFB indication because,” among other things, “there were too many uncertainties with regard to duration of treatment, frequency of administration and endpoints to allow for reliance on a single Phase 3 trial,” and “the conduct of two independent trials would be important in providing replicative evidence supporting an overall demonstration of efficacy and safety.” On this news, shares of Aradigm fell sharply during intraday trading on January 9, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Aradigm investors. If you purchased shares of Aradigm, please visit the firm’s website at http://www.rosenlegal.com/cases-1268.html or more information. You may also contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
09/01/2018

Underlying

ARDMAradigm

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aradigm

 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Announces the EMA Has Completed Its Validation of the MAA Subm...

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa). The completion of the MAA validation is commensurate with the start date of the review procedure on March 29, 2018. The EMA review of the MAA ...

April 5, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter 2017 Results The Company recorded $2.4 million in revenue in the fourth quarter of 2017 compared with $125,000 in revenue in the fourth quarter of 2016. The Company recognized $2.3 million in contract revenue – related party, $27,000 in government contract revenue and $71,000 in government grant revenue for the fourt...

March 23, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who ...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aradigm Corporation (“Aradigm” or the “Company”) (NASDAQ:ARDM) of the March 12, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Aradigm stock or options between July 27, 2017 and January 8, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ARDM. There is no cost or obligation to you. ...

March 9, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

Aradigm Submits Marketing Authorisation Application (MAA) to EMA for E...

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced it has submitted its Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). In accordance with Article 8(3) and Annex I, Part II.7 of Directive 2001/83/EC, Aradigm is submitting a mixed MAA for Linhaliq that is based on the positive Phase 3 pivota...

March 9, 2018 1 EN
 PRESS RELEASE
Free
ARDM ARADIGM

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Aradigm Corporation (Nasdaq: ARDM) (“Aradigm” or the “Company”) securities during the period between July 27, 2017 and January 8, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 12, 2018 to s...

March 3, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch